Obi Greenman
Chief Executive Officer bei CERUS CORPORATION
Vermögen: 6 Mio $ am 31.03.2024
Profil
William Mariner Greenman is currently the President, Chief Executive Officer & Director at Cerus Corp.
He previously served as an Independent Director at Aduro BioTech, Inc. and Chinook Therapeutics, Inc. He also held the position of Senior Vice President-Biotech Division at Baxter International, Inc. Mr. Greenman obtained his undergraduate degree from Stanford University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CERUS CORPORATION
1,75% | 14.03.2024 | 3 181 281 ( 1,75% ) | 6 Mio $ | 31.03.2024 |
Aktive Positionen von Obi Greenman
| Unternehmen | Position | Beginn |
|---|---|---|
| CERUS CORPORATION | Chief Executive Officer | 21.04.2011 |
Ehemalige bekannte Positionen von Obi Greenman
| Unternehmen | Position | Ende |
|---|---|---|
| CHINOOK THERAPEUTICS, INC. | Director/Board Member | 11.08.2023 |
| BAXTER INTERNATIONAL INC. | Corporate Officer/Principal | 01.01.1995 |
| CHINOOK THERAPEUTICS, INC. | Director/Board Member | - |
Ausbildung von Obi Greenman
| Stanford University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BAXTER INTERNATIONAL INC. | Health Technology |
| CERUS CORPORATION | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
Chinook Therapeutics, Inc.
 Chinook Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA. | Health Technology |
